TY  - JOUR
A1  - Janjetovic, Snjezana
A1  - Lohneis, Philipp
A1  - Nogai, Axel
A1  - Balci, Derya
A1  - Rasche, Leo
A1  - Jähne, Doris
A1  - Bokemeyer, Carsten
A1  - Schilling, Georgia
A1  - Blau, Igor Wolfgang
A1  - Schmidt-Hieber, Martin
T1  - Clinical and biological characteristics of medullary and extramedullary plasma cell dyscrasias
JF  - Biology
N2  - Background: Extramedullary plasma cell (PC) disorders may occur as extramedullary disease in multiple myeloma (MM-EMD) or as primary extramedullary plasmocytoma (pEMP)/solitary osseous plasmocytoma (SOP). In this study, we aimed to obtain insights into the molecular mechanisms of extramedullary spread of clonal PC. Methods: Clinical and biological characteristics of 87 patients with MM-EMD (n = 49), pEMP/SOP (n = 20) and classical MM (n = 18) were analyzed by using immunohistochemistry (CXCR4, CD31, CD44 and CD81 staining) and cytoplasmic immunoglobulin staining combined with fluorescence in situ hybridization (cIg-FISH). Results: High expression of CD44, a cell-surface glycoprotein involved in cell-cell interactions, was significantly enriched in MM-EMD (90%) vs. pEMP/SOP (27%) or classical MM (33%) (p < 0.001). In addition, 1q21 amplification by clonal PC occurred at a similar frequency of MM-EMD (33%), pEMP/SOP (57%) and classical MM (44%). Conversely, del(17p13), t(4;14) and t(14;16) were completely absent in pEMP/SOP. Besides this, 1q21 amplification was identified in 64% of not paraskeletal samples from MM-EMD or pEMP compared to 9% of SOP or paraskeletal MM-EMD/pEMP and 44% of classical MM samples, respectively (p = 0.02). Conclusion: Expression of molecules involved in homing and cytogenetic aberrations differ between MM with or without EMD and pEMP/SOP.
KW  - plasma cell disorder
KW  - multiple myeloma
KW  - extramedullary
KW  - immunohistochemistry
KW  - cytogenetics
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242592
SN  - 2079-7737
VL  - 10
IS  - 7
ER  - 
TY  - JOUR
A1  - Ullmann, Andrew J.
A1  - Schmidt-Hieber, Martin
A1  - Bertz, Hartmut
A1  - Heinz, Werner J.
A1  - Kiehl, Michael
A1  - Krüger, William
A1  - Mousset, Sabine
A1  - Neuburger, Stefan
A1  - Neumann, Silke
A1  - Penack, Olaf
A1  - Silling, Gerda
A1  - Vehreschild, Jörg Janne
A1  - Einsele, Hermann
A1  - Maschmeyer, Georg
T1  - Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
JF  - Annals of Hematology
N2  - Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.
KW  - Bone-marrow-transplantation
KW  - Pneumocystis-carinii-pneumonia
KW  - Influenzae type B
KW  - Respiratory syncytial virus
KW  - Infections
KW  - invasive fungal infections
KW  - Varicella-Zoster-Virus
KW  - Hepatitis B virus
KW  - Herpes simplex virus
KW  - Human immunodefiency virus
KW  - Low-dose acyclovir
KW  - Viral
KW  - Fungal
KW  - Bacteria
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187587
VL  - 95
IS  - 9
ER  - 
TY  - JOUR
A1  - Mousset, Sabine
A1  - Buchheidt, Dieter
A1  - Heinz, Werner
A1  - Ruhnke, Markus
A1  - Cornely, Oliver A.
A1  - Egerer, Gerlinde
A1  - Krüger, William
A1  - Link, Hartmut
A1  - Neumann, Silke
A1  - Ostermann, Helmut
A1  - Panse, Jens
A1  - Penack, Olaf
A1  - Rieger, Christina
A1  - Schmidt-Hieber, Martin
A1  - Silling, Gerda
A1  - Südhoff, Thomas
A1  - Ullmann, Andrew J.
A1  - Wolf, Hans-Heinrich
A1  - Maschmeyer, Georg
A1  - Böhme, Angelika
T1  - Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
JF  - Annals of Hematology
N2  - Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive Candida infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection.
KW  - cancer
KW  - invasive fungal infections
KW  - antifungals
KW  - mycoses
KW  - hematologic malignancies
KW  - aspergillosis
KW  - antifungal agents
KW  - invasive candidiasis
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121340
VL  - 96
ER  -